XML 44 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangement - Additional Information (Detail) - USD ($)
3 Months Ended
May. 09, 2016
Apr. 05, 2016
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Paid-in-kind interest     $ 1,168,000 $ 33,000    
Sanofi-Aventis Deutschland GmbH            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Carrying value     63,500,000   $ 44,500,000  
Sanofi-Aventis Deutschland GmbH | Mortgage Loan            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Carrying value     $ 17,700,000      
License and Collaboration Agreement with Sanofi            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage     35.00%      
Maximum secured loan facility           $ 175,000,000
Senior notes, effective interest rate           8.50%
License and Collaboration Agreement with Sanofi | Subsequent Event            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage   35.00%        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage     65.00%      
Collaboration agreements expiration date     Apr. 04, 2016      
Deferred revenue from collaboration product shipments     $ 150,000,000      
Milestone receivable     50,000,000      
Deferred cost     13,500,000      
Company's total portion of loss sharing     5,500,000      
Maximum secured loan facility     175,000,000      
Carrying value     63,500,000      
Secured loan facility, amount borrowed     63,500,000      
Secured loan facility, amount owed     68,800,000      
Paid-in-kind interest     2,800,000      
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Company's total portion of loss sharing     68,800,000      
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue from collaboration product shipments     $ 17,700,000      
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Subsequent Event            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Profits and losses sharing percentage   65.00%        
Secured loan facility, amount borrowed $ 5,300,000